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This issue of Dynamis presents a collection of articles on the beginnings of 
a biological treatment: diphtheria serotherapy. This therapy contributed to 
a decisive change in public and private behaviours towards cases of infec-
tious/contagious disease. The phrase «herald of the new medicine», which 
appears in the title of this introduction, was used by the Spanish Health 
Council to describe the treatment of diphtheria by serum taken from the 
blood of immunised horses, i.e., the Behring-Roux method. This new the-
rapy had been reported to the Council by Antonio Mendoza and Manuel 
Sanz on their return from official visits to Paris and Berlin in Autumn 1894. 
The description reflects the perception of novelty, of successful innovation 
generated by their report. Articles by Gabriel Gachelin and Jonathan Si-
mon, respectively, offer a detailed analysis of the French side of the initial 
production of serum, while Axel Hüntelmann tels the German side of the 
same story. Annick Opinel addresses the implications of the new therapy 
for hospital practice in her account of the construction of the Pasteur 
Hospital, which was designed to fight against diphtheria. 
This introduction aims to show the relevance of these papers to current 
historiography on the construction of one-cause-medicine, a powerful force 
in the shaping of health, disease and care in the present world.
Diphtheria appeared in industrial countries between the mid-19th 
and mid- 20th centuries as an endemic disease with epidemic outbreaks 
at irregular intervals 1. It has become a fashionable subject of historical 
 1.  BURNET, Macfarlane. Historia de las enfermedades infecciosas, Madrid, Alianza Editorial, 1967; 
CARMICHAEL, Anne. Diphteria. In: Kenneth F. Kiple (ed.), The Cambridge world history of hu-
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interest for several reasons. It was the first typically human disease sub-
jected to the entire programme derived from the new bacteriology. Thus 
a pathogenic germ was established, a biological treatment was developed 
(serum from hyper-immunised animals), a standard susceptibility test was 
created (Shick’s skin test) and, finally, a vaccine was produced, which was 
widely employed to curb and almost eradicate diphtheria in Europe and 
Northern America 2. A worldwide decline in diphtheria cases of around 
70% was recorded between the mid-1970s and the early 1990s. More re-
cently, however, there has been an increased incidence as a skin infection 
and also as endocarditis, with a case-fatality rate of > 40% 3. The collapse 
of the Soviet Union in the 1990s has led to its re-emergence in Europe 
refreshing, with incident rates of 0.5-1 per 100,000 in Armenia, Estonia, 
Lithuania and Uzbekistan and of 27-32 per 100,000 in Russia and Tajikistan, 
while the case-fatality rate ranges from 2 to 23% 4. 
Diphtheria serotherapy has been described as the crucial link between 
public excitement about Pasteur’s rabies vaccine and the establishment of 
national campaigns against tuberculosis, sustaining the development of 
bacteriology-based public health service. This observation, first made in the 
setting of Germany, has been confirmed by independent studies in other 
national settings, including Spain 5. That Emil von Behring (1854-1917), 
who discovered the antitoxic power of sera from hyper-immunised animals, 
man disease, Cambridge, CUP, 1993, 680-683; NEWSHOLME, Arthur. Epidemic diphtheria: a 
research on the origin and spread of the disease from an International Standpoint, s.l., Swan 
Sonnensch and Co. Ltd, 1898; GOTTSTEIN, Adolf. Epidemiologische Studien über Diphterie und 
Scharlach, Berlin, Springer, 1895; MARCO, Luis. La difteria en España y en Madrid, Madrid, Est. 
Tip. E. Teodoro, 1888.
 2. CARMICHAEL, note 1; HARDY, Anne. The epidemic streets: infectious disease and the rise of preven-
tive medicine 1865-1900, London, Clarendon Press, 1993, especially pp. 80-109; HAMMONDS, 
Evelyn M. Childhood’s deadly scourge: the campaign to control diphtheria in New York City, 
1880-1930, Baltimore, The Johns Hopkins University Press, 1999; HOOKER, Claire; BASHFORD, 
Alison. Diphtheria and Australian public health: bacteriology and its complex applications, 
c. 1890-1930. Med. Hist., 2002, 46, 41-64; COLGROVE, James. The power of persuasion: Diph-
theria immunization, advertising, and the rise of health education. Public Health Rep., 2004, 
119, 506-509.
 3.  GRAEVENITZ, A. von. The changing epidemiology of diphtheria in the past two centuries. Ann. 
Ig., 2002, 14 (Suppl. 1), 1-5.
 4.  Data from WHO as of December 2000 [cited 27 February 2007]. Available from: http://www.
who.int/mediacentre/factsheets/fs089/en/
 5.  WEINDLING, Paul. From medical research to clinical practice: serum therapy for diphtheria in 
the 1890s. In: John V. Pickstone (ed.), Medical innovations in historical perspectives, New York, 
St. Martin’s Press, 1992, pp. 72-83; HOOKER, BASHFORD, note 2; PORRAS GALLO, María Isabel. 
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won the first Nobel Prize for Medicine (1901), demonstrates the impact of 
this innovation and the support that it gained. Its wide use and acceptance 
were responsible for changes in the standard behaviour of families, doctors 
and authorities alike towards any suffocating illness in children. It also led to 
new hospital structures and work dynamics, representing a decisive triumph 
for medicine based on microbial aetiology. The unleashing of a complex of 
effects by a single therapeutic innovation fits with general ideas put forward 
by Bourdelais and Faure on the dissemination of novel practices 6.
If all of these considerations do not constitute sufficient argument in 
favour of our compilation, I would presume to claim that these studies 
make us aware of the profound link among disease, diagnosis and treat-
ment, in other words, interactivity between the development of concepts 
and practices in medicine similar to that demonstrated in recent research 
on technologies 7. The new procedures related to the threat of diphtheria 
in the second half of the 19th century, before and after the beginnings 
of bacteriology (e.g., intubation, serotherapy and vaccination) have been 
studied from a social history perspective of innovation, examining the role 
of national and professional cultures in their dissemination 8. This collec-
tion explores the same perspective, focusing on the initial development of 
the complex network used to extend serotherapy and simultaneously the 
Antecedentes y creación del Instituto de Sueroterapia, Vacunación y Bacteriología de Alfonso 
XIII. Dynamis, 1998, 18, 81-105.
 6.  BOURDELAIS, Patrice; FAURE, Olivier (dir.). Les nouvelles pratiques de santé. Acteurs, objets, logiques 
sociales (XVIIIe-XXe siècles), Paris, Belin, 2005.
 7.  PICKSTONE, John V. Introduction. In: Pickstone, note 5, pp. 1-16 (14); MEDINA DOMÉNECH, Rosa 
M.; MENÉNDEZ NAVARRO, Alfredo. Tecnologías médicas en el mundo contemporáneo: una 
visión histórica desde las periferias. Introducción. Dynamis, 2004, 24, 15-26.
 8.  LIEBENAU, Jonathan M. Public health and the production and use of diphtheria antitoxin in 
Philadelphia, Bull. Hist. Med., 1987, 61, 216-236; VELLE, K. Arts, Staat en Volksgezonheid: De 
strijd tegen de difterie in Belgie (1894-1914). Arch. Belg. Med. Soc., 1989, 47, 312-324; HARDY, 
Anne. Tracheotomy versus intubation: surgical intervention in diphtheria in Europe and the 
United States, 1825-1930. Bull. Hist. Med., 1992, 66, 536-559; WEINDLING, note 5 and From 
isolation To therapy: children’s hospitals and diphtheria in Fin de Siècle Paris, London and 
Berlin. In: Roger Cooter (ed.), In the name of the child: health and welfare, 1880-1940, London, 
Routledge, 1992, pp.124-145; RODRÍGUEZ-OCAÑA, Esteban. El tratamiento de la difteria en 
la España de la segunda mitad del siglo diecinueve. Medicina e Historia, nº 54 (3ª época), 
1994, 5-28; THROM, Carola. Das Diphtherieserum. Ein neues Therapieprinzip, seine Entwicklung 
und Markteinführung, Stuttgart, Wissenschaftliche Verlagsgesellschaft, 1995; KABA, Mariama. 
La diphtérie à Génève à la fin du XIXe siècle: l’entrée en scène de la bactériologie et l’emploi 
de la sérothérapie. Gesnerus, 2004, 61, 37-56.
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laboratory culture throughout the Western world, pinpointing differences 
between French and German settings. 
The following papers report changes linked to the widespread use of 
serum, starting with its mass production in Germany and in France after 
mastery of the delicate technique had been achieved and a reliable and regular 
flow of the product could be guaranteed. In fact, the technical procedures 
for artificial immunization were developed as an empirical side-effect of 
research into chemical disinfectants 9. This was followed by international 
standardisation of anti-toxic power measurements and profound changes 
in the pharmaceutical industry (production of antidiphtheric serum was 
sometimes decisive in the birth of new companies) 10. Widespread use of 
serum led to changes in hygienic institutions (as shown here in the case 
study on the Pasteur Institut) as well as the pharmaceutical trade, intro-
ducing some new legal regulations and accelerating various changes in the 
profession. It also contributed to the strengthening of public confidence in 
scientific medicine, especially in the emerging Children’s Medicine, as well 
as endowing the specialty of Hygiene with a laboratory foundation and gene-
rating a network of basic research between the heirs of Pasteur and Koch 11. 
Furhermore, a type of scientific research gained an immediate economic 
dimension that fuelled the promotion of some experts, whose work was 
able to sustain large-scale commercial activity. In many cases, researchers 
who had gained expertise in public laboratories and institutions moved to 
the private sphere, on their own initiative or recruited by companies. The 
subsequent shift in the «moral economy» of biological research became a 
feature that defines present technoscience 12. 
 9.  SIMON, Jonathan. Emil Behring’s medical culture: from disinfection to serotherapy. Med. Hist., 
2007, 51 (2), 201-218.
 10.  LIEBENAU, Jonathan. Medical science and medical industry: the formation of the American phar-
maceutical industry, London/ Baltimore, Macmillan /Johns Hopkins University Press, 1987; 
TANSEY, E.M. The Wellcome physiological research laboratories 1894-1904: The home office, 
pharmaceutical firms and animal experiments. Med. Hist., 1989, 33, 1-41. It is a pity that the 
otherwise overwhelming book by Raúl RODRÍGUEZ NOZAL and Antonio GONZÁLEZ BUENO. 
Entre el arte y la técnica. Los orígenes de la fabricación industrial del medicamento (Madrid, CSIC, 
2005) pays no attention to biological medications.
 11.  WEINDLING, note 5, p. 72. 
 12.  RASMUSSEN, Nicolas. The moral economy of the drug company-medical scientist collabora-
tion in interwar America. Soc. Stud. Science, 2004, 34, 161-185. Particularly interesting, in this 
way, are cases such as those of Emil von Behring and Paul Ehrlich. LINTON, Derek S. Emil von 
Behring: infectious disease, immunology, serum therapy, Philadelphia, American Philosophical 
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A further theoretical effect brought about by 1891-born serotherapy 13 
was to end discussions on the nosotaxy of a disease whose character and 
even name remained controversial during the second half of the 19th century. 
There was debate about the similarities and differences among different 
types of suffocating angina, diphtheria and croup (a separate disease as 
defined by the Scotsman Francis Home in 1765, although numerous similar 
descriptions can be found in the medical literature of the early modern 
era) 14. The lack of consensus led to national division between supporters 
and opponents of a united concept of diphtheria 15. Bacteriological diagno-
sis and especially serotherapy imposed agreement, and modern diphtheria 
acquired a laboratory identity, a processs analysed by Cunningham 16. 
With this background, it is difficult to establish a history of diphtheria 
in the longue durée based solely on clinical narratives of the time, which 
were already questioned at the beginning of the 19th century, when it was 
Society, 2005; SIMON, note 9; HARDY, Anne. Paul Ehrlich und die Serumproduzenten: Zur 
Kontrolle des Diphtherieserums in Labor und Fabrik. Medizinhist. J., 2006, 41, 51-84. In Spain, 
and waiting for deeper studies on the technical personnel of the National Hygiene Institute, 
who created THIF, a firm producing biological medicaments which merged in 1929 with 
IBYS, the best known example is provided by Jaime Ferrán’s life, see RODRÍGUEZ- OCAÑA, E. 
Ferrán y Clúa, Jaime. In: W. F. Bynum & Helen Bynum (eds.), Dictionary of medical biography, 
Westport,CT /London, Greenwood Press, 2007, vol. 2, pp. 486-488. 
 13. First documented case of serotherapy occurred in 1891, managed by Behring and Wernicke. 
OEDINGEN, Christina; STAERK Joseph W. First cure for diphtheria by antitoxin as early as 1891. 
Annals of Science, 1997, 54, 607-610.
 14. Spanish authors described the disease named garrotillo (from the suffocation caused by the 
common device —garrotte— used for executions) in the 16th and 17th centuries, AMORÓS 
SEBASTIÁ, L.I. et al. La difteria y los médicos españoles del Renacimiento. Acta Otorrinolaringol. 
Esp., 2002, 53, 146-150. 
 15. Curiosly, experts from the past and modern ones do not agree upon this divide. SANNÉ, 
Albert. Diphtérie. In: A. Dechambre (ed.), Dictionnaire encylopédique des sciences médicales, Paris, 
P. Asselin/G. Masson, 1884, vol. 29, pp. 548-721 (556-557), put together French and American 
doctors and draws German and British as supporters of the division between croup and 
diphtheria, while HARDY (note 2, p. 85) joins all Anglosaxons into a single group to oppose 
French unitarian doctrine. In Spain, even though both names were employed, unitarianism 
prevailed, RODRÍGUEZ-OCAÑA, note 8. See GUTIÉRREZ RODILLA, Bertha M. Errores concep-
tuales y sus repercusiones terminológicas: el caso del «croup» en la historia de la difteria. 
In: Fernández García; Joaquín; Castillo Ojugas, Antonio (eds.), La medicina popular española. 
Trabajos dedicados al Dr. D. Antonio Castillo de Lucas en el Centenario de su nacimiento. Oviedo: 
ASEMEYA, 1998, for a normativistic perspective of the same debate. 
 16. CUNNINGHAM, Andrew. La transformación de la peste: El laboratorio y la identidad de las en-
fermedades infecciosas. Dynamis, 1991, 11, 27-71; CUNNINGHAM, A.; WILLIAMS, Perry (eds). 
The laboratory revolution in medicine, Cambridge, Cambridge University Press , 1992.
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reported that «in none of them can we found all the appropriate features 
[for diphtheria]» 17. However, new DNA technology has allowed laboratory 
exploration of past times, and bacteria from genus Corynebacterium, with 
no more precision, were recently detected in human remains from Ancient 
Egypt (c. 1550-1080 aC) 18. 
A germ aetiology for diphtheria evolved from studies by Klebs (finding 
of Corynebacterium diphteriae, 1883), Löffler (experimental reproduction of 
the disease in animals, 1884) and Roux and Yersin (discovery of endotoxin, 
1888), although it was not accepted before the large-scale application of 
serotherapy started in 1894-95. Microbes was not included among the follo-
wing causes of diphtheria described in a leaflet distributed to the public by 
the Madrid Health Council in 1888 (Instrucciones populares para prevenir 
el desarrollo y propagación de la difteria): «[...] bad housing, scarce food, 
lack of cleanliness, lack of shelter in cold and humid seasons and in general 
the regrettable abandonment of hygienic commandments [...]». Nascent 
bacteriology had to fight on two fronts at the same time, against the envi-
ronmentalism of hygienists and against the traditions of clinicians.
This new biological therapy helped to settle some other medical dis-
putes around diphtheria. General and local antiphlogistic measures were 
used in therapy, but this pattern changed in the second half of the 19th 
century. Around 1880, a common treatment prescription included emetics 
and tonics, local cauterization with silver nitrate and iron perchloride, 
brushstrokes with potassium permanganate and the tearing out the false 
membranes 19. Tracheotomy, as recommended by Trousseau, was used to 
combat the feared condition of asphyxia 20. A less dramatic alternative to 
this operation was intubation, a procedure that had been used for several 
pathological conditions since 1815. Designated tubage, it was applied to 
treat diphtheric asphyxia in the mid-19th century by French specialists, 
 17. Croup, in Diccionario de ciencias médicas, Madrid, Imp. Mateo Repullés, 1822, vol. 8, pp. 326-363 
(327). 
 18. ZINK, Albert et al. Corynebacterium in Ancient Egypt. Med. Hist., 2001, 45, 267-272.
 19. CADIER. Manual de laringoscopia y laringología. [Being the summary of a series of lectures given 
at the École Pratique of the School of Medicine in 1878 and 1879] translated from the last 
French edition [Manuel de laryngoscopie et de laryngologie, Paris, Delahaye, 1880], Madrid, 
Romero, 1881, pp. 101-102. See HARDY, note 8, pp. 544-545.
 20. Trousseau presented his first experiences in a series of articles appeared in 1833 and 1834 on the 
Journal des Connaisances médicochirurgicales, which were later summarised on the Encyclographie 
des Sciences médicales. Répertoire Général des Sciences Médicales au XIXe siècle... (Bruxelles, Société 
Belge de Librairie, 1841, vol. 9, pp. 191-196: «De la trachéotomie dans le croup»).
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notably Eugène Bouchut (1818-1891), although he used it fewer than half-
a-dozen times before 1879 21. Tracheotomy remained the operation of 
choice until the introduction of technical improvements by the American 
physician Joseph O’Dwyer (1841-1898) between 1885 and 1887, after which 
intubation become a preferred approach, especially in the USA 22. Hardy 
(1992) found a strong reason for this shift in the non-surgical nature of the 
intervention, especially well-suited to the search for legitimization by the 
emerging specialists in Children’s Medicine.
Although both operations initially resolved the critical condition, i.e., 
re-opening the airway, this success could be short-lived, since this purely 
mechanical treatment did not reverse the infection. According to the French 
and Scottish literature, survival rates for all operated patients were 25-30% in 
around 1870 23. Between 1870 and 1889, the survival rate for tracheotomies 
at two hospitals in Geneva was 49-53%, decreasing to 26% in 1890-91 24. 
After serotherapy became available, these figures improved, with a 50% 
reduction in mortality rates. At the beginning of the 20th century, it was 
reported that «[...] a great deal of practitioners who have practiced both 
operations agree nowadays that intubation is the operation of choice and 
tracheotomy that of necessity» 25.
Serotherapy was not without drawbacks, and its massive use revealed 
some hazards. Thus, anaphylaxis was described in 1902. Earlier proposals 
by Roux and others for the prophylactic use of the serum were rapidly 
forgotten. In 1896, major controversy arose in Germany over the death of 
Ernst Langerhans, the 8-yr-old son of a highly regarded physician, after the 
preventive injection of diphtheric serum 26. 
Nevertheless, diphtheria disappeared from the front line of the causes 
of mortality in industrial countries during the 20th century. Thus, specific 
diphtheria mortality in Belgium fell from a rate of 135.90 per 100.000 in 
 21. BOUCHUT, E. Tratado práctico de las enfermedades de los recién nacidos y de los niños de pecho y 
de la segunda infancia, 2ª ed., Madrid, Carlos Bailly-Baillière, 1879, p. 358.
 22. See works by HARDY and RODRÍGUEZ-OCAÑA quoted in note 8.
 23. HARDY, note 8, p. 539.
 24. KABA, note 8, p. 45.
 25. RODRÍGUEZ VARGAS, Alfredo. Intubación de la laringe en el niño y en el adulto, Valladolid, Imp. 
y Lib. de J. Montero, 1908, p. 185; on recorded mortality following tracheotomy, p. 202. The 
original statement comes form the French neurologist and expert in inectious diseases Louis 
Landouzy (1845-1917), as quoted by HARDY, note 8, p. 550. 
 26. HÜNTELMANN, Axel. Das Diphtherie- Serum und der Fall Langerhans. Med. Ges. Gesch., 2005, 
24, 71-104.
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1861-64 to 27.10 in 1896-1900, 12.17 in 1911-13 and 5.24 in 1933-35 27. 
In Spain, this mortality fell by 74.6% between 1911 and 1930 28. The fall is 
usually explained by the massive use of effective methods of immunological 
defence: first serotherapy, starting in autumn 1894, and then the vaccine, 
from 1923 onwards. However, there are reasons to doubt the equation that 
links the use of serotherapy with the reduction in diphtheria, primarily 
because of historic variations in estimates of the numbers involved. Inter-
national research carried out by Arthur Newsholme (1857-1943) in 1898 
concluded that diphtheria was present in all great capitals and populous 
cities in the world but that there were continuous fluctuations in specific 
mortality rates. Hardy attributes this to the different pathogenic strengths 
of the three different strains of C. diphtheriae that are harmful to humans 
and she points out that the birth of serotherapy coincided with a cycle of 
low-intensity diphtheria, which might have produced an overvaluation of 
the benefits of the new treatment 29. Contemporary studies show the co-
existence of typically endemic strains with epidemic clones and of toxogenic 
with non-toxogenic strains 30.
It is indisputable that a rapid consensus was achieved on serotherapy 
and that it was widely used. A survey by the American Pediatric Society 
(1896 and 1897) showed that serotherapy reduced overall diphtheria mor-
tality to 13%, while its use from the first day of the disease illness yielded a 
mortality rate of only 4.9%s 31. In 1901, however, the prominent Austrian 
paediatrician Ludwig Unger (1848-1923) stated that serotherapy was too 
weak a remedy to produce a profound change in the situation and that 
mortality had reached historical maximums in some places, e.g., Trieste and 
Saint Petersburg 32. Nevertheless, serotherapy was supported by a number 
 27. VELLE, K. Arts, Staat en Volksgezonheid: De strijd tegen de difterie in Belgie (1894-1914) Arch. 
Belg. Med. Soc., 1989, 47, 312-324 (318).
 28. PASCUA, Marcelino. Mortalidad específica en España. II Mortalidad por sexos, grupos de edades y 
causas en el periodo 1911-1930. Madrid, Publicaciones oficiales de la Comisión Permanente 
de Investigaciones Sanitarias, Dirección General de Sanidad, 1935, pp. 59-61 and tables 24 
and 25. 
 29. HARDY, notes 2 and 8. 
 30. GRAEVENITZ, note 3.
 31. MARKS, Harry M. «Until the sun of science (…) the true Apollo of medicine has risen»: Collec-
tive Investigation in Britain and America, 1880-1910. Med. Hist., 2006, 50, 147-166 (p. 160).
 32. UNGER, Ludwig. Tratado de enfermedades de los niños, Barcelona, J. Espasa [traslatión of Lehrbuch 
der Kinderkrankheiten in kurzgefasster systematischer Darstellung zum Gebrauche für Studierende 
und Aerzte, Leipzig/Wien, F. Deuticke, 3. Aufl. 1901], p. 611. 
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of statistical studies, e.g., by Victor Chary [La mortalité par diphthérie en 
Europe, avant et après l’application de la sérothérapie; étude statistique, 
Paris, 1900] and Ernst Marx [Die experimentelle Diagnostik, Serumthe-
rapie und Prophylaxe der Infectionskrankheiten, Berlin, A. Hirschwald, 
1902]. On the other hand, the influential practitioner Antonin-Bernard-Jean 
Marfan (1858-1942), himself in favour of serum, also cited other factors in 
his epidemiological explanations and, in 1904 he related the lower mortality 
rate to a lower incidence 33. 
For a variety of reasons, a greater consensus developed on the therapeutic 
usage of serum as the 20th century proceeded. Thus, sera were standardised 
(some English sera were known to lack antitoxic power in comparison with 
continental European products), allowing physicians and pharmacists to 
predict the antitoxic power of each phial 34. There next followed attempts 
to standardise indications for amounts of serum and for the method and 
timing of its administration, a task that took decades. Nevertheless, subcu-
taneous injection, deemed the least efficient way to administer the serum, 
was still being used by most physicians in 1915 35. Other procedures that 
were modified included the asepsis of injections and laboratory diagnosis. 
In many places, e.g., New York, Philadelphia and Paris, health services 
developed a flexible scheme that allowed the rapid collection of samples 
and the fast return of a diagnosis to doctors via the pharmacy or even via 
police stations. However, in Spain and some other countries, obtaining a 
quick bacteriological diagnosis was still unlikely in most cases in 1920, 
because of the lack of laboratory facilities and communication difficulties, 
with a complete absence of any relevant official provision 36. 
The popular acceptance of serum was encouraged by access to an 
abundant supply, mainly thanks to charities, as Mariama Kaba shows in 
Geneva, and government subsidies. A good proof of the popularity of 
the new therapy emerged during the devastating influenza pandemic in 
1918-1919. The public demanded from the authorities a change in public 
patterns of intervention, beyond disinfection and isolation measures to a 
 33. Quote of Marfan as of decembre 1904 In: STATISTIQUE de la diphtérie 1903-1904. Annales 
d’hygiène publique et de médecine légale, 1905, sér. 4, nº.4, 359.
 34. LIEBENAU, note 8, p. 233; HARDY, note 12.
 35. Way defended by LLORENTE, Vicente. Difteria y su curación. Bases en que descansa la acertada 
aplicación de la Seroterapia. Madrid, Suc. Rivadeneyra, 1914.
 36. MURILLO PALACIOS, Francisco. El suero antidiftérico, Madrid, Calpe, 1920.
Esteban Rodríguez-Ocaña 
Dynamis 20 07; 27: 21-31
30
wide use of sera and at a secondary level, vaccines. The use of antidiphtheric 
serum in Spain was so high that the Home Ministry had to order mayors 
and physicians to restrict the therapy so that reserves could be maintained 
for specific cases 37. 
Articles in the present collection address the constitution of this new 
model of anti-infectious practices. Thus, the relevance of basic German-
French research to serology is described. Instead of depicting confrontation, 
as occurred during initial bacteriology investigation into anti-anthrax and 
anti-rabies vaccine, Gabriel Gachelin reports the growing standardization 
of techniques and procedures and the formation of an exchange network 
among researchers and institutions in the two countries. 
Annick Oppinel reports on the broad fight against diphtheria and the 
role of serotherapy. As a result of Roux’s connections with Joseph Grancher 
(1843-1907), head of the infectious disease department of the Hôpital des 
Enfants-Malades, he was able to incorporate basic elements into the design 
of the Pasteur Hospital for meeting any type of contingency, including iso-
lation and disinfection procedures. It should not be forgotten that sera were 
initially and most widely used in hospitals, which saw patients at earlier 
stages of the disease. As a result, they obtained better results and were able 
to improve their image as curative establishments. As Opinel shows, the new 
serum was linked in a beneficial way to new hospital design, new structures 
and routines, which were later applied to any transmissible disease.
Axel Hüntelmann and Jonathan Simon both study the industrial pro-
duction and legal regulation of serum in the two pioneer countries. Cul-
tural, social and political differences between the nations are revealed by 
their distinct regulation road maps and production and sales agents, and 
by the different instruments applied by the state to govern its use. On the 
German side, a strong relationship among science, industry and the state 
is highlighted, such that all obtain important benefits: substantial contracts 
and careers for researchers, therapeutic products with wide acceptance and 
a guaranteed sale, and assurances about the control of health risks to the 
population. On the French side, Simon underlines the charitable image of 
the Institut Pasteur, thanks to the large profits generated by their discovery 
 37. RODRÍGUEZ-OCAÑA, Esteban. La Grip a Barcelona. Un greu problema esporàdic de salut pública. 
Epidèmies de 1889-90 i 1918-19. In: Antoni Roca (ed.), 1891-1991. Cent anys de Salut Pública 
a Barcelona, Barcelona, Institut Municipal de la Salut, 1991, pp. 131-156 (150).
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of the serum. As practically the only repository of new knowledge on bacte-
riology and immunology, it attained special status within the French health 
system. Simon elegantly dissects features peculiar to French administration 
and legislation in relation to this innovation and the place of its birth.
Taken together, these papers draw our attention to the complexity 
of innovations while improving our knowledge of the industrial dimen-
sion of basic biological sciences and showing the relevance of the local 
setting in which they are developed and disseminated. I believe that they 
make a good fit with recent studies on social defence against diphtheria 
and contribute useful suggestions for this line of research, which indeed 
would notably improve when including the investigation of perceptions of 
different publics. ❚ 

